Aug 13, 2020 / 08:00PM GMT
Max Masucci - Canaccord Genuity Corp., Research Division - Analyst
Hi. Welcome to the 40th Annual Canaccord Genuity Global Growth Conference. I'm Max Masucci, lead diagnostics analyst here at Canaccord. Today, I'm pleased to be joined by Guardant Health, one of the most transformative companies in health care and the market leader in blood-based liquid biopsy test for therapy selection.
Last Friday, Guardant achieved a milestone that we consider a landmark event in the precision medicine space when its Guardant360 test became the first FDA-approved liquid biopsy that is clinically and analytically validated for all solid tumor cancers. Guardant is just scratching the surface in a $50 billion-plus U.S. market and has additional shots on goal and disease monitoring and early cancer screening. So I'm pleased to welcome back CEO, Helmy Eltoukhy. Thanks again for joining us this year.
Helmy Eltoukhy - Guardant Health, Inc. - Co-Founder, CEO & Director
Thank you for having me, Max.
Guardant Health Inc at Canaccord Genuity Growth Conference (Virtual) Transcript
Aug 14, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers